When fertility becomes more difficult, the next step is not always another generalized protocol. A careful evaluation can clarify whether diminished ovarian reserve, poor ovarian response, hormonal imbalance, or another underlying factor is shaping your options. That context matters before considering any regenerative treatment.
PRP therapy for fertility uses a concentrated preparation of a patient’s own blood platelets, which contain growth factors that may support ovarian tissue, follicular development, and egg quality. Early findings are encouraging for some women, but PRP is still an emerging treatment and cannot guarantee improved fertility or pregnancy.
At National Wellness Group, PRP is considered within the Road to Fertility program rather than as a stand-alone promise. The process begins with understanding your history, cycle patterns, testing, metabolic health, and fertility goals. From there, your care team can explain what ovarian rejuvenation involves, who may be considered, and how it differs from established fertility treatments.
What Is PRP Therapy for Fertility?
Platelet-rich plasma (PRP) is a regenerative treatment prepared from a patient’s own blood. After a blood draw, the sample is processed to concentrate platelets within a smaller volume of plasma. Those platelets contain signaling proteins and growth factors that may support tissue repair and cellular activity when delivered to a targeted area. In fertility care, the goal is to explore whether this concentrated biologic preparation can support the ovarian environment and, in selected cases, follicular development.
PRP therapy for fertility is not the same as ovarian stimulation, in vitro fertilization (IVF), or a supplement protocol. Fertility medications are used to influence follicle recruitment and ovulation within a specific treatment cycle. IVF retrieves eggs for fertilization outside the body. PRP is instead investigated as a localized regenerative intervention, typically involving administration near or within reproductive tissue. The proposed mechanism is biological support, not a guarantee that ovarian reserve, egg quality, or pregnancy outcomes will improve.
How the cellular approach is different
Growth factors released by concentrated platelets may communicate with surrounding cells and help create conditions that support tissue healing and function. Researchers are studying whether that signaling can benefit ovarian tissue in women with diminished ovarian reserve, premature ovarian insufficiency, or a poor response to prior fertility treatment. The evidence remains developing, so treatment decisions should be based on a full review of ovarian reserve, hormone patterns, medical history, age, and reproductive goals. Current research is encouraging but limited, and stronger controlled studies are still needed.
At National Wellness Group, PRP is considered within the Road to Fertility™ program rather than presented as a standalone answer. Dr. Marina Yuabova, DNP, APRN, evaluates the broader factors that may influence fertility, including metabolic health, nutrition, hormonal balance, and prior treatment response. For additional context on the broader evaluation of ovarian health, review this guide to low ovarian reserve natural treatment. A personalized consultation can clarify whether a regenerative option belongs in your fertility strategy and what questions should be addressed before proceeding.
How PRP Ovarian Rejuvenation Works
Intraovarian PRP is designed to deliver concentrated, platelet-derived growth factors directly to ovarian tissue. The preparation is made from the patient’s own blood. After the platelets are concentrated, a clinician places the PRP into the ovaries. With the goal of creating a local environment that may support follicular activity and ovarian function.
The proposed mechanism is regenerative rather than hormonal. Platelets contain signaling proteins involved in tissue repair and cellular communication. When PRP is introduced into ovarian tissue, these growth factors may influence the surrounding environment and support the development of follicles. Follicles contain the immature eggs that may later mature for ovulation or retrieval. Researchers are also evaluating whether this treatment may improve oocyte quality, although the biological response can vary considerably from one patient to another. This remains an area of active investigation, not a guaranteed fertility outcome.
What the 2016 clinical origin means
The use of PRP for ovarian rejuvenation in the setting of diminished ovarian reserve was first reported by a clinical group in Greece in 2016. That milestone helped prompt additional interest in whether platelet-derived growth factors could support ovarian function for women facing reduced reserve or a poor response to stimulation. The field has continued to develop, but the evidence is still emerging and should be interpreted with appropriate clinical caution.
How response is monitored
Follow-up is an important part of the process. Clinicians may monitor Anti-Mullerian Hormone, or AMH, and other fertility markers over the months after treatment. Researchers and fertility providers commonly evaluate AMH approximately one to three months after PRP application when assessing a potential ovarian response. AMH is one data point, not a complete measure of egg quality or the likelihood of pregnancy. A thoughtful review considers laboratory findings alongside age, cycle patterns, prior treatment response, ultrasound findings, metabolic health, and reproductive goals.
At National Wellness Group, PRP is considered within a broader concierge root-cause approach and the Road to Fertility program, rather than presented as a standalone solution. The clinical conversation may include factors that influence reproductive health before treatment, such as nutrient status, hormone balance, inflammation, metabolic function, sleep, and lifestyle. For patients preparing for assisted reproduction, this broader planning may also include how to improve egg quality before IVF. The appropriate next step is an individualized review to determine whether PRP therapy for fertility fits the patient’s history and goals.
Who Can Benefit from PRP for Fertility
PRP may be considered when ovarian function or implantation has remained a concern despite a careful fertility evaluation. The patients most often discussed in current research include women with diminished ovarian reserve (DOR), premature ovarian insufficiency (POI), or poor ovarian response (POR) during assisted fertility treatment. A systematic review describes intraovarian PRP as an intervention being investigated in women with these diagnoses, while also noting that the evidence remains mixed and requires careful interpretation. Read the research review.
Diminished ovarian reserve and premature ovarian insufficiency
DOR means that ovarian reserve markers or the response to stimulation suggest fewer available follicles than expected. POI involves reduced ovarian function at a younger age and requires individualized medical assessment. PRP is not intended to reverse either diagnosis. Instead, it may be evaluated as an adjunctive option when the clinical picture, treatment history, and goals make it reasonable to explore additional support for ovarian function.
Patients researching a broader plan may also benefit from reviewing our low ovarian reserve natural treatment guide. That conversation should address the full preconception picture rather than focus on one procedure or one laboratory value.
Poor ovarian response during IVF
Some women produce fewer follicles or eggs than anticipated during ovarian stimulation. This history may prompt a discussion of whether PRP has a place alongside a future treatment cycle. The decision depends on factors such as age, ovarian reserve testing, prior stimulation results, overall health, and the fertility specialist’s recommendations. PRP should never be presented as a way to guarantee more eggs, improved egg quality, or a successful IVF outcome.
Recurrent implantation failure
PRP has also been explored for patients who have experienced repeated implantation failure during IVF. In that setting, the evaluation must remain comprehensive. Embryo factors, uterine anatomy, endometrial development, timing, inflammation, and other clinical considerations may all matter. PRP may be one tool under consideration, not a substitute for identifying and addressing the factors that could be limiting implantation.
Why the larger fertility plan matters
At National Wellness Group, PRP is positioned within a concierge fertility strategy, not as a standalone fix. A personalized plan may include reviewing medical history, metabolic and hormonal health, nutritional status, environmental exposures, and preconception priorities before deciding whether an adjunctive therapy is appropriate. Our preconception health optimization approach helps place that decision in the context of the whole patient. Eligibility is determined through an individualized consultation, and current evidence does not support promising a specific fertility result.
What to Expect During PRP Treatment
PRP treatment is planned around your fertility history, ovarian or endometrial findings, and current treatment goals. The process is individualized, but most protocols follow a clear sequence.
Consultation and evaluation
Your clinician reviews your medical and fertility history, prior testing, medications, and treatment response. Imaging and laboratory data help determine whether PRP is appropriate and whether the focus should be ovarian, endometrial, or part of a broader fertility plan. This evaluation may also identify opportunities for preconception health optimization before the procedure.
Blood collection
Because PRP is autologous, it is prepared from your own blood. A typical protocol may collect approximately 10 to 60 milliliters, depending on the treatment plan and processing method. Using your own blood minimizes concerns related to donor material and allergic reactions, although every procedure still carries potential risks that should be discussed during consultation.
PRP preparation
The collected blood is placed in a centrifuge to separate and concentrate the platelet-rich portion of the plasma. Platelets contain growth factors being studied for their potential role in supporting ovarian tissue and follicular development. The resulting PRP is prepared for use during the same treatment session.
Intraovarian injection
When the treatment plan involves the ovaries, the clinician delivers PRP directly into the ovarian tissue using image guidance. One published fertility protocol describes an injection of approximately 2 cc into each ovary. The exact approach, anesthesia or sedation plan, and eligibility requirements vary by patient and clinical setting. This procedure should not be presented as a guaranteed way to improve egg quality or achieve pregnancy.
Recovery and follow-up
Some patients experience temporary pelvic discomfort, cramping, spotting, or fatigue after treatment. Your care team provides individualized instructions about activity, warning signs, and when to call. Follow-up testing may include ultrasound, ovarian reserve markers such as AMH, or other fertility assessments. AMH response is commonly evaluated over approximately one to three months, rather than immediately.
For endometrial cases, the follow-up schedule may be more immediate. An ultrasound is often performed within 48 to 72 hours to assess the uterine lining and guide next steps. Your clinician will explain which measurements matter for your situation and whether additional treatment is appropriate.
PRP therapy for fertility is an emerging option, not a substitute for a complete fertility evaluation. A careful consultation helps clarify whether its potential benefits, limitations, and risks fit your individual path.
PRP for Endometrial Receptivity and Implantation
The first reported use of PRP in fertility medicine was not ovarian. In 2015, clinicians used it in women with a thin uterine lining during assisted reproductive treatment. The goal was to support the endometrium, the tissue that must become receptive before an embryo can implant. This early application helped establish PRP as an area of interest for patients whose lining remained inadequate despite standard preparation.
How intrauterine PRP is used
For an endometrial application, a clinician collects a sample of the patient’s blood and processes it to concentrate platelets and their associated growth factors. The prepared PRP is then delivered into the uterine cavity through an intrauterine infusion. The exact timing depends on the fertility protocol and the patient’s response to endometrial preparation. In one commonly described approach, the lining is assessed around days 10 to 12 of an artificial cycle using estrogen. Then PRP is considered when additional support is appropriate.
Clinicians may use a target thickness of at least 7 mm before a frozen embryo transfer and 8 mm before a fresh transfer. These thresholds are clinical goals, not guarantees of implantation. Endometrial quality involves more than a single measurement, so ultrasound findings and the broader treatment plan still matter.
Monitoring the response
A follow-up ultrasound is typically performed 48 to 72 hours after treatment to assess the endometrium and determine whether further preparation is needed. The purpose is not simply to document a number. The care team is evaluating whether the lining appears to be developing in a way that supports the planned transfer and whether the timing remains appropriate.
PRP growth factors may influence local tissue repair, vascular support, and other processes involved in endometrial receptivity. Researchers are therefore studying whether this approach can improve the conditions for embryo attachment and implantation. However, PRP therapy for fertility remains an emerging treatment, and evidence is still developing. A thicker lining does not remove other factors that affect outcomes, including embryo quality, uterine anatomy, inflammation, hormonal timing, and overall health.
That broader context is important when preparing for transfer. Factors outside the uterus may also deserve attention, including the relationship between gut health and fertility. A concierge fertility evaluation can help determine whether endometrial PRP fits the individual case. What conventional preparation has already been attempted, and how the response should be monitored before proceeding.
What Research Says About PRP for Fertility
PRP is an emerging adjunctive therapy in reproductive medicine, not a standalone answer to infertility. The research is developing across ovarian and endometrial applications, with early findings that justify further study while still requiring careful interpretation. A 2026 systematic review noted that controlled evidence remains limited and that results should be viewed cautiously until larger, better-designed studies are available. Review the current evidence on PRP research before treating preliminary findings as established care.
| What Early Research Suggests | What Remains Uncertain |
|---|---|
| Intraovarian PRP is being investigated for people with diminished ovarian reserve, premature ovarian insufficiency, or poor ovarian response. Early studies suggest possible changes in ovarian function, including AMH levels measured during the months after treatment. | AMH improvement does not automatically demonstrate improved egg quality, embryo quality, or pregnancy outcomes. Studies have used different patient groups, treatment methods, and outcome measures. |
| Researchers are exploring whether concentrated platelets and their growth factors may support follicular development and ovarian tissue activity. Some early reports also describe potential improvements in endometrial thickness, an important consideration for implantation. | There are not yet enough large, controlled trials to establish who benefits most, how long an effect lasts, or whether PRP consistently improves live-birth rates. Follicular or lining changes should not be presented as guaranteed fertility outcomes. |
| The timeline reflects two areas of investigation. PRP was first used in fertility medicine for thin endometrial lining in 2015. Its use for ovarian rejuvenation was first reported by a Greek clinical group in 2016. See the reported PRP fertility timeline. | These origin points mark the beginning of clinical use, not proof of universal effectiveness. Protocols continue to vary, including preparation, dose, injection site, number of treatments, and follow-up. More rigorous research is needed to compare approaches directly. |
That uncertainty is why PRP should be evaluated within a comprehensive root-cause fertility plan. A careful review may include ovarian reserve, cycle patterns, metabolic health, inflammation, prior treatment history, and partner factors. For patients with pregnancy losses, recurrent pregnancy loss testing may be relevant before selecting an adjunctive therapy. In the Road to Fertility™ model, PRP is considered only when the clinical picture supports it. Alongside restoration and optimization work, rather than as a replacement for individualized fertility care.
Frequently Asked Questions
How does PRP for ovarian rejuvenation work?
PRP is prepared from your own blood and concentrated to retain platelets and growth factors. When it is administered to the ovaries, the goal is to support the local environment involved in follicular development and ovarian function. The treatment is intended to complement, not replace, individualized fertility evaluation and care.
Who may be a candidate for PRP fertility treatment?
PRP may be considered for women with diminished ovarian reserve, premature ovarian insufficiency, or a poor response during IVF. Candidacy depends on your age, ovarian reserve testing, prior treatment history, overall health, and fertility goals. A consultation should determine whether the potential rationale is appropriate for your case.
How soon can ovarian response be evaluated after treatment?
Clinicians may monitor ovarian markers such as anti-Mullerian hormone, or AMH, approximately one to three months after treatment when assessing a possible response. This is one part of follow-up and does not by itself predict egg quality, embryo development, pregnancy, or live birth.
Is PRP therapy for fertility proven to improve live birth rates?
Not yet. Early findings have generated interest, but the evidence remains limited and studies are ongoing. A recent review noted conflicting findings and limited controlled data, so PRP should be discussed as an emerging option rather than a guaranteed fertility treatment. Review the current evidence.
Can PRP help with a thin uterine lining?
PRP has also been studied as a way to support endometrial lining thickness, which may matter for embryo implantation. The first reported reproductive use was for a thin uterine lining in 2015. Whether it is appropriate depends on the cause of the lining concern and your broader fertility plan.
Ready to Apply for a Consultation?
PRP may be one consideration within a broader fertility plan, but the right next step depends on your history, goals, and evaluation. To discuss whether this approach fits your situation, apply for a consultation with National Wellness Group. Dr. Yuabova and the Road to Fertility team can review your case and outline appropriate next steps with care and clinical perspective.